- Market Capitalization, $K 12,357,295
- Shares Outstanding, K 1,103,330
- Annual Sales, $ 15,878 M
- Annual Income, $ 417,000 K
- 60-Month Beta 1.31
- Price/Sales 0.78
- Price/Cash Flow 3.04
- Price/Book 1.26
|Period||Period Low||Period High||Performance|
| || |
+4.02 (+57.35%)since 07/15/22
| || |
+3.12 (+39.44%)since 05/16/22
| || |
+1.29 (+13.24%)since 08/16/21
Warren Buffett’s diversified holding company Berkshire Hathaway exited its position in drugmaker TEVA by the end of 2021 at a loss of approximately $365 million on its four-year-long bet. However, Buffett...
Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.
There are countless historical chart examples of high volume moves that mark the beginning of sustained rallies or slumps. Let’s tune into a few examples.
Bank of America finds its inner bull with the generics producer.
Berkshire Hathaway cut bait with the struggling drugmaker Teva Pharmaceutical Industries in late 2021.
Stocks that traded heavily or had substantial price changes Wednesday:
TEVA earnings call for the period ending June 30, 2022.
TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25...
The drugmaker's opioid litigation may soon be resolved.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2022.
|Teva Pharmaceutical Industries Ltd ADR|
|Vaneck Pharmaceutical ETF|
|Vaneck Israel ETF|
|Usaa MSCI Intl Value Momentum Blend Index ETF|
|FTSE Intl Low Beta EW Invesco ETF|
|FTSE RAFI Dev Markets Ex-U.S. Invesco ETF|
|3rd Resistance Point||11.46|
|2nd Resistance Point||11.34|
|1st Resistance Point||11.18|
|1st Support Level||10.90|
|2nd Support Level||10.78|
|3rd Support Level||10.62|